Drugs / CYP-006TK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05165628 | Jan 2022 → Sep 2024 | ulcer disease, ulcer of lower limbs | Cynata Therapeutics Limited | Completed | Met primary |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Cynata Therapeutics Limited | Regulatory WHO Selects Proposed INN for Cymerus MSCs cynata.com ↗ |
| 2024-12-04 | Cynata Therapeutics Limited | Results Demonstrated Safety & Efficacy in DFU Clinical Trial cynata.com ↗ |
| 2024-08-07 | Cynata Therapeutics Limited | Results Study of Cymerus MSCs in Pulmonary Fibrosis Published cynata.com ↗
The study found that bleomycin injury resulted in the expected features of the pulmonary fibrosis model, which were ameliorated by a single or double intravenous administration of Cymerus™ MSCs. |
| 2024-02-25 | Cynata Therapeutics Limited | Results Encouraging Initial Data from CYP-006TK DFU Trial cynata.com ↗
The median percentage reduction in wound surface area in the active CYP-006TK group after 10 weeks was 87.6%, compared to 51.1% in the control group (n=8 per group) |
| 2022-06-13 | Cynata Therapeutics Limited | Results Further data supports potency of Cynata MSCs cynata.com ↗ |
| 2021-06-29 | Cynata Therapeutics Limited | Regulatory Ethics Approval for Cynata's Clinical Trial in DFU cynata.com ↗ |
| 2020-05-07 | Cynata Therapeutics Limited | Regulatory Ethics Approval to Commence Clinical Trial in COVID-19 cynata.com ↗ |
| 2019-12-04 | Cynata Therapeutics Limited | Results Cymerus MSCs Effective in Preclinical Model of Sepsis cynata.com ↗
Cynata Therapeutics Limited (ASX: CYP), announced today that it has received positive efficacy data from preclinical studies of its Cymerus™ mesenchymal stem cells (MSCs) in a model of sepsis. |
| 2019-09-03 | Cynata Therapeutics Limited | Results Cynata transplant rejection study accepted for publication cynata.com ↗
Cymerus™ MSC treatment demonstrated effects expected to prevent organ transplant rejection |
| 2019-03-03 | Cynata Therapeutics Limited | Results Positive Pre-Clinical Coronary Artery Disease Data for CYP cynata.com ↗ |
| 2019-02-24 | Cynata Therapeutics Limited | Results Further Cynata Asthma Study Published cynata.com ↗
Cymerus MSCs alone demonstrated striking anti -fibrotic effects, and reduced airway hyperresponsiveness by up to 75% |
| 2018-10-17 | Cynata Therapeutics Limited | Results MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies cynata.com ↗
Engineered Cymerus cells showed highly p romising therapeutic benefits in different mouse tumour models. |
| 2018-09-18 | Cynata Therapeutics Limited | Results Cynata MSCs Ameliorate CRS in Preclinical Study cynata.com ↗
Cymerus MSC treatment is effective in protecting against CRS in murine models , with statistically significant improvements in body temperature and clinical scores relative to control animals. |
| 2018-05-30 | Cynata Therapeutics Limited | Results Cynata's MSCs Effective in Model of Diabetic Wounds cynata.com ↗ |
| 2018-02-04 | Cynata Therapeutics Limited | Results Cynata Engineered MSC Study Review Reveals Promising Results cynata.com ↗ |
| 2017-12-11 | Cynata Therapeutics Limited | Results Final Preclinical Asthma Study Confirms Efficacy cynata.com ↗
Treatment with C ymerus MSCs in clinically -relevant model cause d significantly greater reduction of airway hyperresponsiveness, airway remodelling and fibrosis compared to corticosteroid treatment |
| 2017-08-22 | Cynata Therapeutics Limited | Results Positive Data from CYP MSCs in 2nd Preclinical Asthma Study cynata.com ↗ |
All press releases naming this drug 23 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYP-006TK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05165628 ↗ |
| Known as | Cymerus MSCs | “CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing” NCT05165628 ↗ |